The history of electroCore
We were co-founded in 2005 by JP Errico, Thomas J. Errico, MD, former president of the North American Spine Society, Charles Theofilos, MD, and Peter Staats, MD, former president of the North American Neuromodulation Society. The founders shared a mutual belief that neuromodulation represented a tremendous opportunity for safer and more effective treatments across a variety of conditions.
Our first human studies were completed in emergency room patients and tested the ability of VNS to treat asthma.
We completed our first cluster headache study in 2014. Soon after, in 2015, we announced that we would be initiating two pivotal studies in the acute treatment of cluster headache.
In April 2017, we received FDA clearance for the acute treatment of pain associated with episodic cluster headache. We began commercial distribution in the US shortly after.
In January 2018, we received FDA clearance for the acute treatment of pain associated with migraine headache.
In June 2018, we announced an IPO with the Nasdaq Global Select Market and began trading under ECOR.
In November 2018, we received FDA clearance for the adjunctive use for the preventive treatment of cluster headache.
In March 2020, we received FDA clearance for the preventive treatment of migraine headache in adult patients.
In July 2020, gammaCore Sapphire™ CV (nVNS) receives EUA to treat patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow.
In February 2021, we received FDA clearance for the acute and preventive treatment of migraine in adolescents 12 to 17 years of age.
In September 2021, we received FDA clearance to treat Paroxysmal Hemicrania and Hemicrania Continua